CTRI/2022/02/040348已完成3 期
ââ?¬Å?A Multicentric, Randomized, Double Blind, Parallel Group, Placebo Controlled, Comparative, Prospective and Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Imeglimin Tablets in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone.ââ?¬?
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 216
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or Female Patients aged between 18 to 65 years (both inclusive) with diagnosis of Type 2 diabetes mellitus.
- •2. Treatment naÃ?¯ve patients with inadequately controlled with diet and exercise therapy alone for at least 3 months prior to screening and having inadequate glycemic control at screening defined as HbA1c levels of > 7.0% to ââ?°Â¤ 8.5%.
- •3. Women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study. WOCBP must have a negative urine pregnancy test at screening / baseline visit.
- •4. Patients with no abnormality on 12-lead ECG at screening / baseline visit.
- •5. Patient with ability to understand and provide written informed consent form, which must have been obtained prior to screening.
- •6. Patients willing to comply with the protocol requirements.
排除标准
- •1. Patients with a history of Type 1 diabetes mellitus or secondary diabetes mellitus or diabetes insipidus.
- •2. Patients with a history of metabolic acidosis or diabetic ketoacidosis.
- •3. Patients with Fasting Plasma Glucose (FPG) > 200 mg/dL at screening (If FPG is > 200 mg/dL at screening, FPG will be repeated within 1 week. If repeat FPG is > 200 mg/dL, patient will be excluded from the study).
- •4. Patients with Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 [using the Modification of Diet in Renal Disease (MDRD) equation] at screening.
- •5. Patients with clinically significant impaired hepatic function (SGOT & SGPT more than 3X the UNL and/or Total bilirubin more than 2X the UNL) at screening.
- •6. Patients with a history of congestive heart failure defined as New York Heart Association (NYHA) class III/IV, unstable or acute congestive heart failure.
- •7. Patients with significant cardiovascular history defined as: myocardial infarction, unstable angina pectoris, transient ischemic attack, unstable or previously undiagnosed arrhythmia, cardiac surgery or revascularization (coronary angioplasty or bypass grafts), or cerebrovascular accident.
- •8. Patients with uncontrolled hypertension with sitting systolic BP ââ?°Â¥ 160 mmHg and/or diastolic BP ââ?°Â¥ 100 mmHg at screening.
- •9. Any abnormality on 12-lead ECG at screening that in the opinion of the investigator is clinically significant and is judged as potential risk for patientââ?¬•s participation in the study.
- •10. Patients with a history of anaemia or haemoglobinopathy and/or haemoglobin < 10 g/dL for men; haemoglobin < 9 g/dL for women at screening.
- •11. Patients with known hypersensitivity to any of the ingredients of study medication.
- •12. Patients receiving treatment with systemic corticosteroids.
- •13. Pregnant or breast-feeding, or expecting to conceive within the projected duration of the study.
- •14. Female patients who are of childbearing potential and who are neither surgically sterilized nor willing to use reliable contraceptive methods (like hormonal, barrier methods or intrauterine device).
- •15. Patients with history of any malignancy.
- •16. Patients with known case of infection with hepatitis B, hepatitis C or HIV.
- •17. Patients with donation or transfusion of blood, plasma, or platelets within the past 3 months prior to screening.
- •18. Patients with a history of substance abuse or dependence that in the opinion of the Investigator is considered to interfere with the patientââ?¬•s participation in the study.
- •19. Patients with concurrent participation in another clinical trial or any investigational therapy within 30 days prior to signing informed consent.
- •20. Patients currently taking any of the prohibited medications(s) and inability/unwillingness to discontinue them for the entire study period.
- •21. Suspected inability or unwillingness to comply with the study procedures.
- •22. Patient with any condition which, in the judgment of the Investigator, may render the patient unable to complete the study or which may pose a significant risk to the patient.
研究者
相似试验
已完成
3 期
A clinical study to assess the efficacy and safety of combination of Azilsartan and Amlodipine Tablets in patients with hypertension.CTRI/2022/02/040081Inventia Healthcare Ltd309
已完成
3 期
A clinical study to investigate the effect of fixed dose combination of Pregabalin plus Mecobalamin plus Nortriptyline Tablets for the treatment of diabetic peripheral neuropathic pain with coexistent Vitamin B12 deficiency in adult patients.CTRI/2020/12/029792Synokem Pharmaceuticals Ltd210
尚未招募
3 期
A Multicentric Randomized Double Blind Double Dummy Parallel Group Comparative Phase III Clinical Study to Evaluate the Efficacy Safety and Tolerability in subjects with Uncontrolled Essential Hypertension with stable Coronary Artery Disease (CAD).CTRI/2022/11/047055Ajanta Pharma Limited
招募中
3 期
Diabetic Peripheral Pain Coexisting with Vitamin B12 deficiency to treat with FDC of Pregabalin plus Methylcobalamin plus Duloxetine (Delayed Release) Capsules.CTRI/2024/01/062147Ravenbhel Healthcare Pvt. Ltd.
尚未招募
3 期
A clinical study to assess the efficacy and safety of Pregabalin, Duloxetine and Mecobalamin Capsules in neuropathic pain patients.CTRI/2024/03/063691Synokem Pharmaceuticals Ltd